FightMND \u5df2\u4e3a\u8be5\u7814\u7a76\u63d0\u4f9b\u4e86 881,085 \u6fb3\u5143\u7684\u8d44\u91d1\u627f\u8bfa\uff0c\u5176\u4e2d\u7b2c\u4e00\u671f\u4e3a201,615 \u6fb3\u5143<\/a>\u3002<\/p>\nFightMND \u662f\u6fb3\u5927\u5229\u4e9a\u6700\u5927\u7684 MND \u7814\u7a76\u72ec\u7acb\u57fa\u91d1\uff0c\u4e00\u65e6 PharmAust \u5b8c\u6210\u5176\u65b0\u5236\u9020\u7684 MPL \u8868\u7684\u4e3a\u671f\u4e00\u4e2a\u6708\u7684GMP \u52a0\u901f\u7a33\u5b9a\u6027\u7814\u7a76\uff0c\u5c06\u652f\u4ed8\u5176\u7b2c\u4e8c\u671f 99,230 \u6fb3\u5143\u3002<\/p>\n
\u8ba1\u5212\u5728\u4e0b\u4e2a\u6708\u8fdb\u884c\u7684\u8bd5\u9a8c\u5f00\u59cb\u540e\uff0c\u5c06\u652f\u4ed8\u7b2c\u4e09\u671f 173,034 \u6fb3\u5143\u3002<\/p>\n
\u4e3a\u4e86\u76d1\u7763\u548c\u652f\u6301 1 \u671f\u8bd5\u9a8c\uff0cPharmAust \u4efb\u547d\u4e86 Alithia\u3002<\/p>\n
\u8be5\u7814\u7a76\u7684\u76ee\u7684\u662f\u8bc4\u4f30 MPL \u5728 MND \u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002\u5b83\u8fd8\u5e0c\u671b\u786e\u5b9a MPL \u53ef\u4ee5\u51cf\u7f13\u75be\u75c5\u8fdb\u5c55\u7684\u4efb\u4f55\u8ff9\u8c61\u3002<\/p>\n
\u8be5\u8bd5\u9a8c\u7684\u6570\u636e\u5c06\u4e0e\u52a8\u7269\u7814\u7a76\u76f8\u7ed3\u5408\uff0c\u4ee5\u786e\u5b9a\u662f\u5426\u4f1a\u8fdb\u884c 2 \u671f\u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n
mTOR\u6291\u5236\u5242<\/h2>\n
PharmAust \u5c06 MPL \u8bbe\u8ba1\u4e3a mTOR \u901a\u8def\u7684\u6291\u5236\u5242\uff0c\u8be5\u901a\u8def\u5bf9\u764c\u75c7\u751f\u957f\u548c\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u5177\u6709\u5173\u952e\u5f71\u54cd\u3002<\/p>\n
MPL \u5728\u4eba\u7c7b\u548c\u72ac\u79d1\u52a8\u7269\u7684 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u663e\u793a\u51fa\u6297\u764c\u6d3b\u6027\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002 \u6fb3\u5927\u5229\u4e9a\u7a0e\u52a1\u5c40\u548c AusIndustry \u5171\u540c\u7ba1\u7406\u8054\u90a6\u653f\u5e9c\u7684\u7814\u53d1\u7a0e\u6536\u6fc0\u52b1\u8ba1\u5212\uff0c\u8be5\u8ba1\u5212\u5141\u8bb8\u7b26\u5408\u6761\u4ef6\u7684\u516c\u53f8\u5c31\u7814\u53d1\u6d3b\u52a8\u4ea7\u751f\u7684\u8d39\u7528\u83b7\u5f97\u9ad8\u8fbe 43.5% \u7684\u53ef\u9000\u7a0e\u7a0e\u6536\u62b5\u514d\u3002 \u201c\u6211\u4eec\u611f\u8c22\u6fb3\u5927\u5229\u4e9a\u653f\u5e9c\u5bf9\u6211\u4eec\u7814\u53d1\u8ba1\u5212\u4e2d\u5f00\u5c55\u7684\u5173\u952e\u5de5\u4f5c\u7684\u6301\u7eed\u652f\u6301\u548c\u8ba4\u53ef\uff0c\u201dPharmAust \u8d22\u52a1\u603b\u76d1 Sam Wright \u8bf4\u3002 \u201c\u6536\u5230\u7814\u53d1\u9000\u6b3e\u52a0\u5f3a\u4e86 PharmAust \u5728\u6211\u4eec\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u8d22\u52a1\u72b6\u51b5\uff0c\u201d\u4ed6\u8865\u5145\u8bf4\u3002 \u5373\u5c06\u8fdb\u884c\u7684monepantel\u4e34\u5e8a\u8bd5\u9a8c PharmAust \u6b63\u51c6\u5907\u5bf9\u5176\u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5 (MND) \u4e2d\u7684\u5148\u5bfc\u836f\u7269monepantel (MPL) \u8fdb\u884c 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002 \u672c\u6708\u65e9\u4e9b\u65f6\u5019\uff0cPharmAust \u900f\u9732\uff0cFightMND \u5df2\u4e3a\u8be5\u7814\u7a76\u63d0\u4f9b\u4e86 881,085 \u6fb3\u5143\u7684\u8d44\u91d1\u627f\u8bfa\uff0c\u5176\u4e2d\u7b2c\u4e00\u671f\u4e3a201,615 \u6fb3\u5143\u3002 FightMND \u662f\u6fb3\u5927\u5229\u4e9a\u6700\u5927\u7684 MND \u7814\u7a76\u72ec\u7acb\u57fa\u91d1\uff0c\u4e00\u65e6 PharmAust \u5b8c\u6210\u5176\u65b0\u5236\u9020\u7684 MPL \u8868\u7684\u4e3a\u671f\u4e00\u4e2a\u6708\u7684GMP \u52a0\u901f\u7a33\u5b9a\u6027\u7814\u7a76\uff0c\u5c06\u652f\u4ed8\u5176\u7b2c\u4e8c\u671f 99,230 \u6fb3\u5143\u3002 \u8ba1\u5212\u5728\u4e0b\u4e2a\u6708\u8fdb\u884c\u7684\u8bd5\u9a8c\u5f00\u59cb\u540e\uff0c\u5c06\u652f\u4ed8\u7b2c\u4e09\u671f 173,034… Continue reading PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":13473,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[241],"yoast_head":"\nPharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-19T07:00:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:53:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Amplia-Therapeutics-ASX-ATX-research-and-development-tax-incentive-refund-FAK-inhibitors-science-biotech.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/\",\"name\":\"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-04-19T07:00:46+00:00\",\"dateModified\":\"2023-08-29T17:53:45+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5","description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5","og_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/","og_site_name":"smallcapsCN","article_published_time":"2022-04-19T07:00:46+00:00","article_modified_time":"2023-08-29T17:53:45+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Amplia-Therapeutics-ASX-ATX-research-and-development-tax-incentive-refund-FAK-inhibitors-science-biotech.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/","url":"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/","name":"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-04-19T07:00:46+00:00","dateModified":"2023-08-29T17:53:45+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8 PharmAust (ASX: PAA) \u56e0\u5176\u5168\u8d44\u5b50\u516c\u53f8 Epichem \u548c Pitney Pharmaceuticals \u5f00\u5c55\u7684\u5de5\u4f5c\u83b7\u5f97\u4e86 708,000 \u6fb3\u5143\u7684\u7814\u53d1 (R&D) \u9000\u7a0e\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-receives-rd-tax-refund-strengthen-financial-position-upcoming-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"PharmAust \u83b7\u5f97 708,000 \u6fb3\u5143\u7684\u7814\u53d1\u9000\u7a0e\uff0c\u52a0\u5f3a\u4e86\u5373\u5c06\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8d22\u52a1\u72b6\u51b5"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4999"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4999"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4999\/revisions"}],"predecessor-version":[{"id":14878,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4999\/revisions\/14878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13473"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}